Results 51 to 60 of about 72,745 (302)
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad +17 more
wiley +1 more source
Einstein (São Paulo), 2020 Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she ...
José Roberto Mendes Pegler +3 more
doaj +2 more sources
Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
Frontiers in Immunology, 2023 Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens.
Stephan von Gunten +3 more
doaj +1 more source
Guillain-Barré syndrome: a century of progress [PDF]
, 2016 In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts — novel findings that identified the disease we now know as Guillain–Barré syndrome (GBS).
A Campbell +91 more
core +1 more source
Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia.
Japanese Journal of Clinical Immunology, 2002 Intravenous immunoglobulin (IVIG) replacement therapy is the mainstay of therapy for X linked agammaglobulinemia (XLA). This study was attempted to investigate how patients with XLA were treated with IVIG in Japan. Data were complied from questionnaires filled in by the physicians.
Hirokazu, Kanegane +3 more
openaire +3 more sources
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Current Oncology, 2022 Secondary antibody deficiency (SAD) is a common complication in chronic lymphocytic leukemia (CLL) which favors the development of life-threatening infections.
Andrea Visentin +11 more
doaj +1 more source
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
Molecular Oncology, EarlyView.PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta +10 more
wiley +1 more source
Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
Therapeutics and Clinical Risk Management, 2012 Philip WoodSt James University Hospital, Leeds, United KingdomAbstract: The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common.
Wood P
doaj